IFW Sy

IN THE UNITED STATES PARENT AND TRADEMARK OFFICE

Applicant

: Koichi SHUDO et al.

Confirmation No.: 5124

Application No.: 10/577,487

Group Art Unit: 1614

(U.S. National Phase of PCT/JP2004/016363)

MAY 1 2 2009

Examiner: Not Yet Assigned

I.A. Filed

: 10/28/2004

For

: MEDICAMENT FOR THERAPEUTIC AND/OR PREVENTIVE

TREATMENT OF RESTENOSIS OR REOCCLUSION AFTER

VASCULAR RECANALIZATION OPERATION

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop <u>AMENDMENT</u>
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and further to the Information Disclosure Statements filed November 9, 2006 and February 10, 2009, Applicants hereby direct the Examiner's attention to the following documents cited in the Partial European Search Report for European Application EP 07 01 5427, of which the above-referenced application is a counterpart application:

- (1) US 6 117 859, Applicants note that this document was listed in the Information Disclosure Statement of November 9, 2006;
- (2) EP 0 221 221 A, Applicants note that this document was listed in the Information Disclosure Statement of November 9, 2006;
- (3) JP 37 000 225 B, January 23, 1962, accompanied by an English language abstract thereof;
- (4) WO 99/55663 A1, Applicants note that this document was listed in the Information Disclosure Statement of November 9, 2006;

05/13/2009 SHOHAMHE 00000018 10577487

01 FC:1806

180.00 OP

- (5) EP 0 221 346 A1, Applicants note that this document was listed in the Information Disclosure Statement of November 9, 2006;
- (6) WO 00/35442 A1, Applicants note that this document was listed in the Information Disclosure Statement of November 9, 2006;
- (7) EP 0 081 782 A1, June 22, 1983
- (8) WO 99/65449 A1, Applicants note that this document was listed in the Information Disclosure Statement of November 9, 2006;
- (9) MADAN et al., Molecular Pharmacology, 2000, Vol. 58, No. 3., pp. 526-534, Applicants note that this document was listed in the Information Disclosure Statement of November 9, 2006; and
- (10) JP 62 099329 A1, Applicants note that this document was listed in the Information Disclosure Statement of November 9, 2006.

Furthermore, Applicants direct the Examiner's attention to the following document:

(11) EP 1 113 000 A1, April 7, 2001; Applicants note that this document was cited in the Supplementary European Search Report for European Application EP 03 73 0837, which was inadvertently omitted in the Seventh Supplemental Information Disclosure Statement, filed February 10, 2009.

Copies of the above-listed documents (3), (7) and (11) and the Partial European Search Report for European Application EP 07 01 5427 are enclosed together with a completed copy of the Form PTO-1449 listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the Form PTO-1449 with the next communication.

Applicants note that a non-final Office Action has issued in the instant application on May 7, 2009. Therefore, to ensure consideration of the enclosed materials pursuant to 37 C.F.R. § 1.97(c), Applicants submit herewith the requisite fee under 37 C.F.R.

1.17(p). If for any reason the requisite fee is not enclosed herewith or any additional fee is required, the undersigned authorizes the Office to charge Deposit account 19-0089 any fee necessary to ensure the consideration of the submitted materials.

Should the Examiner have any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully submitted, Koichi SHUDO et al.

Bruce H. Bernstei

Reg. No. 29,027

1950 Roland Clarke Place

GREENBLUM & BERNSTEIN, P.L.C.

May 11, 2009

Reston, VA 20191 (703) 716-1191